WO2005054865A3 - Diagnostics and therapeutics for diseases associated with protein-coupled inwardly rectifying potassium channel (girk1) - Google Patents

Diagnostics and therapeutics for diseases associated with protein-coupled inwardly rectifying potassium channel (girk1) Download PDF

Info

Publication number
WO2005054865A3
WO2005054865A3 PCT/EP2004/012822 EP2004012822W WO2005054865A3 WO 2005054865 A3 WO2005054865 A3 WO 2005054865A3 EP 2004012822 W EP2004012822 W EP 2004012822W WO 2005054865 A3 WO2005054865 A3 WO 2005054865A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
girk1
therapeutics
diagnostics
protein
Prior art date
Application number
PCT/EP2004/012822
Other languages
French (fr)
Other versions
WO2005054865A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts filed Critical Bayer Healthcare Ag
Publication of WO2005054865A2 publication Critical patent/WO2005054865A2/en
Publication of WO2005054865A3 publication Critical patent/WO2005054865A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Abstract

The invention provides a human GIRK1 which is associated with the cardiovascular diseases, gastroenterological diseases, cancer, hematological diseases, neurological diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, gastroenterological diseases, cancer, hematological diseases, neurological diseases and urological diseases,. The invention also features compounds which bind to and/or activate or inhibit the activity of GIRK1 as well as pharmaceutical compositions comprising such compounds.
PCT/EP2004/012822 2003-11-25 2004-11-12 Diagnostics and therapeutics for diseases associated with protein-coupled inwardly rectifying potassium channel (girk1) WO2005054865A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03026924 2003-11-25
EP03026924.5 2003-11-25

Publications (2)

Publication Number Publication Date
WO2005054865A2 WO2005054865A2 (en) 2005-06-16
WO2005054865A3 true WO2005054865A3 (en) 2006-01-12

Family

ID=34639260

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/012822 WO2005054865A2 (en) 2003-11-25 2004-11-12 Diagnostics and therapeutics for diseases associated with protein-coupled inwardly rectifying potassium channel (girk1)

Country Status (1)

Country Link
WO (1) WO2005054865A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670335A (en) * 1993-08-06 1997-09-23 The Regents Of The University Of California Mammalian inward rectifier potasssium channel cDNAs, host cells expressing them, and screening assays using such cells
US6500938B1 (en) * 1998-01-30 2002-12-31 Incyte Genomics, Inc. Composition for the detection of signaling pathway gene expression

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670335A (en) * 1993-08-06 1997-09-23 The Regents Of The University Of California Mammalian inward rectifier potasssium channel cDNAs, host cells expressing them, and screening assays using such cells
US6500938B1 (en) * 1998-01-30 2002-12-31 Incyte Genomics, Inc. Composition for the detection of signaling pathway gene expression

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEN SHU-CHENG ET AL: "Developmental expression of the GIRK family of inward rectifying potassium channels: Implications for abnormalities in the weaver mutant mouse", BRAIN RESEARCH, vol. 778, no. 2, 19 December 1997 (1997-12-19), pages 251 - 264, XP002331537, ISSN: 0006-8993 *
KOBAYASHI TORU ET AL: "Inhibition by various antipsychotic drugs of the G-protein-activated inwardly rectifying K+ (GIRK) channels expressed in Xenopus oocytes", BRITISH JOURNAL OF PHARMACOLOGY, vol. 129, no. 8, April 2000 (2000-04-01), pages 1716 - 1722, XP002331536, ISSN: 0007-1188 *
XU XIANG-HUA ET AL: "mRNA expression alterations of inward rectifier potassium channels in rat brain with cholinergic impairment", NEUROSCIENCE LETTERS, vol. 322, no. 1, 29 March 2002 (2002-03-29), pages 25 - 28, XP002331535, ISSN: 0304-3940 *

Also Published As

Publication number Publication date
WO2005054865A2 (en) 2005-06-16

Similar Documents

Publication Publication Date Title
WO2005093092A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 44 (gpr44)
WO2005076007A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor p2y12 (p2y12)
WO2005075675A3 (en) Diagnostics and therapeutics for diseases associated with putative cysteine protease 1 (prs1)
WO2005054848A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled inwardly rectifying potassium channel (girk2)
WO2005054865A3 (en) Diagnostics and therapeutics for diseases associated with protein-coupled inwardly rectifying potassium channel (girk1)
WO2005093091A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 26 (gpr26)
WO2004082568A3 (en) Diagnostics and therapeutics for diseases associated with complement component 5a receptor (c5ar)
WO2004038405A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 43 (gpr43)
WO2004071378A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor hm74a (hm74a)
WO2005031345A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor adipor2 (adipor2)
WO2005050197A3 (en) Diagnostics and therapeutics for diseases associated with protein-coupled inwardly rectifying potassium channel girk4 (girk4)
WO2005040791A3 (en) Diagnostics and therapeutics for diseases associated with somatostatin- and angiogenin-like peptide receptor (salpr)
WO2005073729A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor p2y11 (p2y11)
WO2005052574A3 (en) Diagnostics and therapeutics for diseases associated with potassium channel subfamily k, member 4 (kcnk4)
WO2005093423A3 (en) Diagnostics and therapeutics for diseases associated with peroxisome proliferative activated receptor alpha (ppara)
WO2004099248A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor agtr2 (agtr2)
WO2004038421A3 (en) Diagnostics and therapeutics for diseases associated with human g protein-coupled receptor 41 (gpr41)
WO2005054863A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled inwardly rectifying potassium channel (girk 3)
WO2004082571A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 86 (gpr86)
WO2005026719A3 (en) Diagnostics and therapeutics for diseases associated with transporter slc22a3 (slc22a3)
WO2004071377A3 (en) Diagnostics and therapeutics for diseases associated with phosphodiesterase 3a (pde3a)
WO2004073591A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep2 (prostaglandin e2 ep2)
WO2005114209A3 (en) Diagnostics and therapeutics for diseases associated with g protein-dependent receptor kinase 2 (grk2)
WO2004071394A3 (en) Diagnostics and therapeutics for diseases associated with hm74
WO2005015203A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled opioid receptor mu 1 (oprm1)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase